Home > Clinical Trials
Check All Search

Saved trials

RECRUITING
NCT06439693
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
72 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
Breast Cancer Female


Breast Cancer


Breast Cancer Metastatic


Estrogen Receptor-positive Breast Cancer


HER2-positive Breast Cancer


Stage IV Breast Cancer
TERMINATED
NCT03248492
A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)
253 Enrollment(s)
99 Study location(s)
INTERVENTIONAL (PHASE2)
Breast Cancer
RECRUITING
NCT06665178
Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer
20 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
Breast Cancer
COMPLETED
NCT04420598
DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease
41 Enrollment(s)
16 Study location(s)
INTERVENTIONAL (PHASE2)
Advanced Breast Cancer


HER2-positive Breast Cancer


Brain Metastases


Leptomeningeal Metastasis
COMPLETED
NCT01777503
The Elderly ACS II Trial
1,457 Enrollment(s)
2 Study location(s)
INTERVENTIONAL (PHASE4)
Acute Coronary Syndrome


Coronary Arteriosclerosis


Myocardial Ischemia


Cardiovascular Diseases
RECRUITING
NCT07030569
RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study
500 Enrollment(s)
1 Study location(s)
OBSERVATIONAL (None)
Radiomic


Radiomics


Breast Cancer Metastatic


Breast Cancer Stage IV


Breast Carcinoma


Breast Neoplasms


Breast Cancer


Breast Cancer With Bone Metastasis


Breast Cancer With Metastatic Bone Disease


Trastuzumab


HER2


HER2 + Breast Cancer


HER2 Positive Breast Carcinoma


HER2-positive Breast Cancer


Her2/Neu Positive Advanced Solid Tumors


HER2/Neu-positive Breast Cancer
ACTIVE_NOT_RECRUITING
NCT04494425
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
866 Enrollment(s)
294 Study location(s)
INTERVENTIONAL (PHASE3)
Advanced or Metastatic Breast Cancer
RECRUITING
NCT06832202
A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients
50 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
HER2-low Hormone Receptor Positive Breast Cancer